Free hemoglobin refers to hemoglobin released from red blood cells into the plasma, typically due to hemolysis or trauma.
Normally confined within red blood cells, hemoglobin is an essential protein responsible for transporting oxygen from the lungs to tissues throughout the body.
In situations of hemolysis, such as hemolytic anemia, blood transfusion reactions, trauma, burns, sepsis, and genetic disorders like sickle cell disease, red blood cells rupture, releasing hemoglobin into the bloodstream.
Free hemoglobin is toxic, possessing oxidative, endothelial-disrupting, and pro-inflammatory properties. Its presence in the bloodstream is linked to adverse outcomes, including acute kidney injury and endothelial dysfunction.
The body has natural scavenger proteins, such as haptoglobin (Hp) and hemopexin (Hpx), to neutralize the harmful effects of free hemoglobin. However, during severe hemolysis, these scavenging systems can become overwhelmed, leading to depletion of nitric oxide, oxidative damage, and widespread inflammation.
Understanding these mechanisms highlights the potential for therapeutic interventions targeting free hemoglobin to improve outcomes in conditions like trauma, sepsis, and hemolytic disorders.
Free hemoglobin refers to hemoglobin that has been released from red blood cells into the plasma.
Normally, hemoglobin is stationed inside red blood cells, where an antioxidant system reduces its oxidative potential. [8.] In situations of hemolysis or trauma, hemoglobin is released into the bloodstream.
Free hemoglobin is known to be toxic, with oxidative, endothelial-disrupting, and pro-inflammatory properties. Its presence in the bloodstream is associated with adverse outcomes, such as acute kidney injury and endothelial dysfunction. [9.]
Hemoglobin (Hb) is a vital protein found in red blood cells, responsible for transporting oxygen from the lungs to tissues throughout the body.
Each hemoglobin molecule is composed of four polypeptide globin chains, forming a tetramer. The most common type of hemoglobin in adults is HbA, consisting of two alpha-globin and two beta-globin subunits.
The synthesis of hemoglobin involves two main processes: globin production and heme synthesis. Globin chain production occurs in the cytosol of erythrocytes, while heme synthesis occurs in both the cytosol and mitochondria.
Genetic transcription and translation regulate globin production, while heme synthesis begins with glycine and succinyl coenzyme A and ends with the production of a protoporphyrin IX ring.
The heme group, which is a component of hemoglobin, is a porphyrin ring coordinated with an iron atom in its center. This porphyrin structure is essential for the binding and transport of oxygen in the bloodstream.
The porphyrin ring is composed of four pyrrole subunits connected by methine bridges. Each pyrrole subunit contains four carbon atoms and one nitrogen atom in a cyclic structure. The central iron atom of the porphyrin ring coordinates with the nitrogen atoms of the pyrrole rings, forming the heme complex.
While the heme porphyrin ring carries iron, other porphyrin structures carry other ionic compounds. Notably, the porphyrin structure of chlorophyll carries magnesium, and the porphyrin structure of vitamin B12, cobalamin, carries cobalt.
Old or damaged red blood cells containing hemoglobin are removed from circulation by macrophages in the spleen and liver, where hemoglobin is broken down into heme and globin.
The heme is converted to bilirubin during metabolism, which is then transported to the liver and secreted in bile.
Fetal hemoglobin (HbF), present primarily during pregnancy, has a higher oxygen affinity than adult hemoglobin, allowing for efficient oxygen extraction from maternal blood through the placenta. Fetal hemoglobin is replaced by adult hemoglobin throughout the first 2 years of life, and adults have only 2-3% of circulating fetal hemoglobin. [7.]
Hemoglobin, a vital protein in red blood cells, has several key functions essential for maintaining physiological balance and responding to metabolic demands.
Primarily, it transports oxygen from the lungs to tissues and organs throughout the body, facilitated by the Bohr effect, which adjusts hemoglobin's oxygen affinity based on carbon dioxide levels and pH. In tissues with high CO2 and lower pH, hemoglobin releases oxygen, while in the lungs, a less acidic environment enhances oxygen binding.
Hemoglobin also plays a role in gas exchange by carrying carbon dioxide from tissues back to the lungs for exhalation and helps buffer blood pH by binding to excess hydrogen ions, preventing acidosis and alkalosis.
Additionally, it regulates blood flow through the release of nitric oxide, causing vasodilation and improving oxygen delivery.
Other functions include maintaining blood volume and pressure by contributing to osmotic balance, supporting fetal development by facilitating oxygen transport from the mother to the fetus, and participating in the immune response by interacting with reactive oxygen and nitrogen species and modulating immune signaling pathways.
Lastly, hemoglobin contributes to iron recycling, essential for maintaining iron homeostasis in the body.
Free hemoglobin is caused by hemolysis, or rupture of red blood cells. A variety of conditions can cause hemolysis.
A condition where RBCs are destroyed faster than they can be produced, leading to the release of hemoglobin into the plasma.
Incompatibility during blood transfusions can cause RBCs to rupture, releasing hemoglobin.
Severe physical injury or infection can lead to hemolysis and the release of free hemoglobin.
Genetic disorders that cause RBCs to become misshapen and break down prematurely.
Cell-free hemoglobin (CFH) or free hemoglobin plays a critical role in the pathophysiology of trauma, both acute and chronic.
It wreaks havoc by promoting four primary pathologies: [9.]
The sudden release of extracellular hemoglobin (Hb) triggers conditions like vascular disease, inflammation, thrombosis, and renal impairment. [15.]
Released from hemolyzed red blood cells during trauma and blood transfusions, CFH overwhelms the body's scavenging mechanisms, leading to the depletion of nitric oxide, oxidative damage, and widespread inflammation.
This process mirrors the injury pathways seen in sepsis and hemolytic disorders, where CFH is a potent mediator of organ dysfunction. [13.]
In trauma patients, elevated CFH levels correlate with injury severity and poor outcomes, as it exacerbates endothelial injury, promotes thrombosis, and triggers inflammatory responses. [13.]
Understanding the specific toxic mechanisms of free hemoglobin highlights the potential for therapeutic interventions targeting CFH to improve outcomes in critically injured patients.
Key mechanisms include Hb's extravascular translocation, oxidative reactions, hemin release, and signaling effects. Natural scavenger proteins, haptoglobin (Hp) and hemopexin (Hpx), show potential in neutralizing these effects, offering therapeutic benefits across diverse conditions like RBC transfusion, sickle cell disease, sepsis, and extracorporeal circulation.
Mechanisms of free hemoglobin toxicity include:
Hb can move out of blood vessels into tissues, leading to damage, especially in kidneys and vascular walls.
Hb reacts with NO and peroxides, reducing NO bioavailability, causing vasoconstriction, and generating harmful oxidative species.
Hemin, released from oxidized Hb, can attach to cell membranes or plasma proteins, promoting inflammation and tissue damage.
Hemin interacts with receptors and enzymes, affecting gene expression and cell activation, contributing to inflammatory responses.
Natural scavengers of free hemoglobin in the bloodstream include:
Haptoglobin scavenges free hemoglobin (Hb) by binding to it and forming a complex that prevents Hb from causing tissue damage.
This binding ensures that Hb remains within the blood vessels, thereby reducing the risk of hypertension and renal injury often associated with free Hb.
Additionally, haptoglobin stabilizes Hb, preventing it from undergoing oxidative reactions and transferring hemin, which could lead to further oxidative stress and tissue damage.
Hemopexin exhibits significant scavenging effects on free hemoglobin by binding hemin with high affinity, effectively preventing its toxic effects.
This binding action protects lipoproteins from hemin-induced oxidative modifications, thereby preventing cell activation that could lead to inflammation and tissue damage.
Additionally, hemopexin facilitates the clearance of hemin through hepatocytes, which are liver cells responsible for processing and eliminating harmful substances from the blood.
Albumin, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) can also bind free heme, aiding in its clearance.
Free hemoglobin (Hb), released during hemolysis, can have both acute and chronic effects on the body.
Acutely, free Hb can cause systemic and pulmonary hypertension by depleting nitric oxide (NO) and causing vasoconstriction. This can lead to immediate vascular complications such as increased blood pressure and subsequent renal injury.
Free Hb in the plasma can also promote oxidative stress through reactions with hydrogen peroxide and lipid peroxides, leading to the formation of ferric Hb (Hb-Fe3+), ferryl Hb (Hb-Fe4+), and associated radicals.
These oxidative reactions can result in tissue damage and inflammation, contributing to acute organ dysfunction.
Chronically, prolonged exposure to free Hb and its degradation products can lead to more complex and insidious pathophysiological changes.
Chronic Hb exposure can cause sustained inflammation, oxidative reactions, and thrombosis, contributing to vascular remodeling and long-term damage to blood vessels and organs such as the kidneys.
This can result in conditions like chronic kidney disease and increased risk of cardiovascular diseases.
Additionally, chronic Hb exposure can lead to ongoing oxidative stress and inflammation, further exacerbating tissue damage and contributing to the progression of diseases such as sickle cell anemia and other hemolytic disorders.
In both acute and chronic scenarios, the body's natural scavenger proteins, haptoglobin (Hp) and hemopexin (Hpx), play a critical role in neutralizing the toxic effects of free Hb and hemin.
However, when these scavenging systems are overwhelmed, such as during severe hemolysis, the resulting free Hb and hemin can lead to significant vascular and organ damage.
High levels of free hemoglobin in the blood can lead to various symptoms and complications, depending on the cause.
High free hemoglobin is often associated with hemolytic anemia, which can cause symptoms such as fatigue, weakness, shortness of breath, dark urine, jaundice or splenomegaly (enlarged spleen), abdominal pain, and pale skin.
Free hemoglobin can lead to vascular issues, potentially causing:
Increased free hemoglobin can result in:
In sickle cell disease, uncomplicated pain episodes have been associated with increases in plasma hemoglobin levels.
Free hemoglobin is typically assessed in serum or plasma. During the procedure, a small sample of blood is drawn from a vein in the arm using a needle.
No special preparation is usually required for the hemoglobin test. Patients can typically eat and drink normally before the test and do not need to fast; however, strenuous exercise should be avoided.
Free hemoglobin in the bloodstream is a pathological finding. Optimally, free hemoglobin should be absent, or very low.
Elevated free hemoglobin levels outside the setting of acute trauma typically indicate a hemolytic process. Further assessment is required.
The assessment of free hemoglobin levels is often complemented by the measurement of other related biomarkers, providing a more comprehensive evaluation of hemolytic conditions and their associated pathologies.
Haptoglobin is a plasma protein that binds to free hemoglobin, forming a stable complex. This binding helps to prevent the oxidative and inflammatory effects of free hemoglobin in the circulation.
Decreased levels of haptoglobin can indicate the presence of hemolysis, as haptoglobin swiftly becomes depleted due to its binding to free hemoglobin and the subsequent clearance of this complex from circulation.
Lactate dehydrogenase (LDH) is an enzyme present in various tissues, including red blood cells.
During hemolysis, LDH is released into the bloodstream, leading to elevated serum or plasma levels. Measurement of LDH can aid in the diagnosis and monitoring of hemolytic conditions, as well as other conditions associated with tissue damage.
Bilirubin is a byproduct of hemoglobin breakdown, formed during the normal recycling of aged or damaged red blood cells.
Increased levels of bilirubin, particularly unconjugated bilirubin, can indicate the presence of hemolysis and the subsequent breakdown of free hemoglobin.
The measurement of free hemoglobin levels, along with related biomarkers, has various clinical applications in the diagnosis, monitoring, and management of various conditions.
One of the primary applications of free hemoglobin testing is in the diagnosis and monitoring of hemolytic conditions, such as hemolytic anemias, transfusion reactions, and trauma-induced hemolysis.
Elevated levels of free hemoglobin, coupled with changes in related biomarkers like haptoglobin and LDH, can aid in the identification and assessment of the severity of these conditions.
Free hemoglobin has been studied as a potential biomarker for assessing the severity and prognosis of various diseases, including preeclampsia and certain cancers. [8., 14.]
In preeclampsia, elevated levels of free hemoglobin and related biomarkers may indicate hemolysis, including chronic hemolysis. The presence of fetal free hemoglobin relates to the severity of preeclampsia. [8.]
The measurement of free hemoglobin levels is crucial in the evaluation of hemolytic transfusion reactions, which can occur when incompatible blood products are transfused.
Elevated levels of free hemoglobin, along with other markers like LDH and bilirubin, can help identify and manage these potentially life-threatening reactions.
In certain therapeutic interventions, such as chemotherapy and immunotherapy, hemolysis can occur as a side effect.
Monitoring free hemoglobin levels and related biomarkers can aid in assessing the extent of hemolysis and guiding appropriate management strategies.
Free hemoglobin refers to hemoglobin that is present in the plasma outside of red blood cells. Normally, hemoglobin is contained within red blood cells and is responsible for transporting oxygen from the lungs to tissues and carbon dioxide from tissues back to the lungs.
Free hemoglobin in the blood can occur due to the breakdown (hemolysis) of red blood cells. Causes of hemolysis include:
Free hemoglobin is measured through blood tests, including:
Symptoms of high free hemoglobin levels can vary depending on the underlying cause and the severity of hemolysis. They may include:
High levels of free hemoglobin can lead to several health issues, including:
Treatment for high free hemoglobin levels focuses on addressing the underlying cause of hemolysis. Possible treatments include:
While lifestyle changes alone cannot directly manage free hemoglobin levels, maintaining overall health can support the management of conditions that may lead to hemolysis. Consider:
For more information about free hemoglobin and related conditions, consider consulting:
Click here to compare testing options and order testing for hemoglobin and related biomarkers.
[1.] 005595: Hemoglobin (Hb), Free, Plasma | Labcorp. Labcorp. Published 2021. Accessed June 24, 2024. https://www.labcorp.com/tests/005595/hemoglobin-hb-free-plasma
[2.] Allen BW, Stamler JS, Piantadosi CA. Hemoglobin, nitric oxide and molecular mechanisms of hypoxic vasodilation. Trends Mol Med. 2009 Oct;15(10):452-60. doi: 10.1016/j.molmed.2009.08.002. Epub 2009 Sep 24. PMID: 19781996; PMCID: PMC2785508.
[3.] Benner A, Patel AK, Singh K, et al. Physiology, Bohr Effect. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526028/
[4.] Billett HH. Hemoglobin and Hematocrit. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 151. Available from: https://www.ncbi.nlm.nih.gov/books/NBK259/
[5.] Dean L. Blood Groups and Red Cell Antigens [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2005. Chapter 1, Blood and the cells it contains. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2263/
[6.] DynaMedex. www.dynamedex.com. Accessed June 24, 2024. https://www.dynamedex.com/condition/overview-of-hemolytic-anemias-in-children
[7.] Farid Y, Bowman NS, Lecat P. Biochemistry, Hemoglobin Synthesis. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536912/
[8.] Gram M, Anderson UD, Johansson ME, Edström-Hägerwall A, Larsson I, Jälmby M, Hansson SR, Åkerström B. The Human Endogenous Protection System against Cell-Free Hemoglobin and Heme Is Overwhelmed in Preeclampsia and Provides Potential Biomarkers and Clinical Indicators. PLoS One. 2015 Sep 14;10(9):e0138111. doi: 10.1371/journal.pone.0138111. Erratum in: PLoS One. 2020 Feb 26;15(2):e0229816. doi: 10.1371/journal.pone.0229816. PMID: 26368565; PMCID: PMC4569570.
[9.] Jungner Å, Vallius S, Gram M, Ley D. Cell-Free Hemoglobin Concentration in Blood Prime Solution Is a Major Determinant of Cell-Free Hemoglobin Exposure during Cardiopulmonary Bypass Circulation in the Newborn. J Clin Med. 2022 Jul 14;11(14):4071. doi: 10.3390/jcm11144071. PMID: 35887835; PMCID: PMC9317140.
[10.] Kulasekararaj A, Kuter DJ, Griffin M, Weitz IC, Röth A. Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition. 2023;59:101041-101041. doi:https://doi.org/10.1016/j.blre.2023.101041
[11.] Liu A, Curtis S, Sebastiani P, Brambilla D, Glassberg JA. Plasma Free Hemoglobin Is Associated with LDH, AST, Total Bilirubin, and the Hemolytic Component in Patients with Sickle Cell Anemia. Blood. 2022;140(Supplement 1):5438-5439. doi:https://doi.org/10.1182/blood-2022-158713
[12.] Marengo-Rowe AJ. Structure-function relations of human hemoglobins. Proc (Bayl Univ Med Cent). 2006 Jul;19(3):239-45. doi: 10.1080/08998280.2006.11928171. PMID: 17252042; PMCID: PMC1484532.
[13.] Ross JT, Robles AJ, Mazer MB, Studer AC, Remy KE, Callcut RA. Cell-Free Hemoglobin in the Pathophysiology of Trauma: A Scoping Review. Critical care explorations. 2024;6(2):e1052-e1052. doi:https://doi.org/10.1097/cce.0000000000001052
[14.] Rytting M, Worth L, Jaffe N. Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am. 1996 Apr;10(2):365-76. doi: 10.1016/s0889-8588(05)70343-9. PMID: 8707760.
[15.] Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013 Feb 21;121(8):1276-84. doi: 10.1182/blood-2012-11-451229. Epub 2012 Dec 20. PMID: 23264591; PMCID: PMC3578950.